Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Y-27632 (hydrochloride hydrate)

Y-27632 hydrochloride hydrate is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with Kis of 220 and 300 nM, respectively. Y-27632 hydrochloride hydrate attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 hydrochloride hydrate also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 hydrochloride hydrate primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation[1][2][3][4][5][6][7].

Product Specifications

CAS Number

[331752-47-7]

UNSPSC

12352005

Hazard Statement

H302-H312-H332

Target

Apoptosis; Organoid; ROCK

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; Stem Cell/Wnt; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/y-27632-hydrochloride-hydrate.html

Smiles

O=C([C@H]1CC[C@](CC1)([H])[C@H](N)C)NC2=CC=NC=C2.Cl.O.Cl

Molecular Formula

C14H25Cl2N3O2

Molecular Weight

338.27

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P501

References & Citations

[3]Inan S, et al. Antiepileptic effects of two Rho-kinase inhibitors, Y-27632 and fasudil, in mice. Br J Pharmacol. 2008 Sep;155 (1) :44-51.|[4]Ishizaki T, et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000 May;57 (5) :976-83.|[5]Tada S, et al. A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. J Hepatol. 2001 Apr;34 (4) :529-36.|[6]Kan L, et al. Rho-Associated Kinase Inhibitor (Y-27632) Attenuates Doxorubicin-Induced Apoptosis of Human Cardiac Stem Cells. PLoS One. 2015;10 (12) :e0144513. Published 2015 Dec 8.|[7]Maldonado M, et al. ROCK inhibitor primes human induced pluripotent stem cells to selectively differentiate towardsmesendodermal lineage via epithelial-mesenchymal transition-like modulation. Stem Cell Res. 2016 Sep;17 (2) :222-227.|[8]Zhang L, et al. ROCK inhibitor Y-27632 suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells and increases their cloning efficiency. PLoS One. 2011;6 (3) :e18271. Published 2011 Mar 28.|[1]Svoboda KK, et al. ROCK inhibitor (Y27632) increases apoptosis and disrupts the actin cortical mat in embryonic avian corneal epithelium. Dev Dyn. 2004;229 (3) :579-590.|[2]Xue ZW, et al. Rho-associated coiled kinase inhibitor Y-27632 promotes neuronal-like differentiation of adult human adipose tissue-derived stem cells.Chin Med J (Engl) . 2012 Sep;125 (18) :3332-5.

Shipping Conditions

Room temperature

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Citation 01

Biomedicines. 2022 Apr 18;10 (4) :928. |ACS Appl Mater Interfaces. 2022 May 25;14 (20) :23219-23231.|ACS Biomater Sci Eng. 2022 Mar 14;8 (3) :1301-1311.|ACS Biomater Sci Eng. 2023 Feb 13;9 (2) :856-868.|ACS Nano. 2025 Aug 19;19 (32) :29073-29086.|ACS Omega. 2025 Apr 22;10 (17) :17228-17236.|Acta Neuropathol Commun. 2024 Sep 14;12 (1) :150.|Acta Neuropathol Commun. 2025 May 27;13 (1) :118.|Acta Pharm Sin B. 2023 Jul;13 (7) :3027-3042.|Adv Healthc Mater. 2021 May;10 (10) :e2002103.|Adv Healthc Mater. 2025 Sep 18:e01846.|Adv Mater Interfaces. 2024 Sep 03.|Adv Mater. 2025 May 28:e2419768.|Adv Redox Res. 2025 Sep.|Adv Sci (Weinh) . 2020 Jun 17;7 (15) :1903583.|Adv Sci (Weinh) . 2024 Feb;11 (5) :e2303088.|Adv Sci (Weinh) . 2024 May 20:e2307216.|Adv Sci (Weinh) . 2025 Apr 13:e2413376.|Adv Sci (Weinh) . 2025 Nov 3:e09151.|Adv Ther. 2024 April 30.|Adv Ther. 2024 Jul 18.|Anal Chem. 2017 Oct 17;89 (20) :10841-10849.|Ann Surg Oncol. 2024 Mar;31 (3) :1996-2007.|Antioxid Redox Signal. 2025 Jul 25.|Arch Oral Biol. 2025 Jan:169:106115.|Autophagy. 2025 Jul 09.|Bioact Mater. 2021 Jun 1:7:364-376.|Bioact Mater. 2022 Aug 14:21:69-85.|Bioact Mater. 2023 Mar 20:26:413-424.|Bioact Mater. 2024 Jun 14:40:244-260.|Bioact Mater. 2025 Nov 25:57:646-659.|Biochem Biophys Rep. 2022 Jul 2:31:101299.|Biochem Biophys Res Commun. 2019 Aug 20;516 (2) :571-577.|Biochem Biophys Res Commun. 2019 Oct 29;519 (1) :134-140.|Biochem Biophys Res Commun. 2023 Aug 6:668:8-18.|Bioengineered. 2022 Apr;13 (4) :8747-8758.|Bioengineering (Basel) . 2020 Dec 18;7 (4) :164.|Biol Reprod. 2025 May 13:ioaf108.|Biology (Basel) . 2023 Jun 20;12 (6) :888.|Biomater Adv. 2024 Feb:157:213751.|Biomater Adv. 2025 Apr 9:174:214316.|Biomater Res. 2025 Nov 7:29:0280.|Biomater Res. 2025 Oct 22.|Biomaterials. 2020 May;240:119849.|Biomaterials. 2020 Nov;258:120284.|Biomaterials. 2024 Mar:305:122462.|Biomed Pharmacother. 2022 Sep:153:113465.|Biomed Pharmacother. 2025 Apr 3:186:118025.|Biomed Res Int. 2021 May 14:2021:5565748.|Biomedicines. 2024 Nov 27;12 (12) :2708.|Biophys J. 2025 Sep 2;124 (17) :2840-2853.|bioRxiv. 2020 Aug.|bioRxiv. 2020 Mar.|bioRxiv. 2023 Dec 6.|bioRxiv. 2023 Feb 24:2023.02.24.529861.|bioRxiv. 2023 Jul 1.|bioRxiv. 2023 Jun 22.|bioRxiv. 2023 Jun 28.|bioRxiv. 2023 Mar 1.|bioRxiv. 2024 Aug 12:2024.08.12.607571.|bioRxiv. 2024 Feb 18.|bioRxiv. 2024 Nov 15:2024.11.13.623500.|bioRxiv. 2024 November 15.|bioRxiv. 2024 November 26.|bioRxiv. 2024 September 07.|bioRxiv. 2025 April 03.|bioRxiv. 2025 April 30.|bioRxiv. 2025 Aug 09.|bioRxiv. 2025 Feb 22:2025.02.17.638725.|bioRxiv. 2025 January 15.|bioRxiv. 2025 Jun 18.|bioRxiv. 2025 March 25.|bioRxiv. 2025 May 09.|bioRxiv. 2025 Sep 8:2025.09.05.671511.|bioRxiv. January 16, 2022.|Biosci Biotechnol Biochem. 2021 Sep 22;85 (10) :2137-2144.|BMC Cancer. 2023 Jun 22;23 (1) :577.|BMC Pulm Med. 2023 Dec 13;23 (1) :505.|BMC Urol. 2021 Jan 6;21 (1) :5.|Bone Res. 2022 Jan 3;10 (1) :1.|Br J Cancer. 2025 Aug 26.|Brain Res. 2021 Dec 15:1773:147684.|Can Respir J. 2022 Oct 10:2022:6879539.|Cancer Cell Int. 2024 Jul 25;24 (1) :263.|Cancer Cell. 2023 Jun 12;41 (6) :1103-1117.e12.|Cancer Cell. 2024 Jun 10;42 (6) :1086-1105.e13.|Cancer Commun (Lond) . 2025 Nov 10.|Cancer Lett. 2019 Apr 28:448:117-127.|Cancer Med. 2024 Nov;13 (21) :e70397.|Cancer Res. 2023 Feb 3;83 (3) :398-413.|Cancer Res. 2025 Aug 29.|Cancer Res. 2025 Nov 6.|Cancer Res. 2025 Oct 9.|Cancers (Basel) . 2021 Jun 30;13 (13) :3282.|Cell Biochem Biophys. 2024 Mar;82 (1) :127-137.|Cell Biol Toxicol. 2025 Aug 20;41 (1) :126.|Cell Biosci. 2024 May 22;14 (1) :65.|Cell Death Dis. 2022 Aug 24;13 (8) :730.|Cell Death Dis. 2023 Apr 20;14 (4) :280.|Cell Death Dis. 2024 Aug 3;15 (8) :559.|Cell Death Dis. 2025 May 14;16 (1) :380.|Cell Death Discov. 2023 Jan 25;9 (1) :32.|Cell Discov. 2021 Apr 19;7 (1) :25.|Cell Discov. 2022 Apr 19;8 (1) :35.|Cell Genom. 2025 Jul 9;5 (7) :100881.|Cell Mol Biol Lett. 2025 Jan 29;30 (1) :14.|Cell Prolif. 2022 Apr;55 (4) :e13209.|Cell Prolif. 2023 Jan;56 (1) :e13320.|Cell Prolif. 2024 Jun;57 (6) :e13599.|Cell Prolif. 2025 Jul 16:e70097.|Cell Regen. 2020 Sep 3;9 (1) :15.|Cell Rep Med. 2023 Feb 21;4 (2) :100911.|Cell Rep Med. 2025 Feb 18;6 (2) :101966.|Cell Rep Methods. 2024 Aug 27:100843.|Cell Rep Methods. 2024 May 8:100777.|Cell Rep Phys Sci. 2025 Oct 15;6 (10) .|Cell Rep. 2023 May 2;42 (5) :112445.|Cell Rep. 2023 Oct 5;42 (10) :113213.|Cell Rep. 2025 Nov 25;44 (11) :116505.|Cell Rep. 2019 Jan 8;26 (2) :407-414.e5.|Cell Res. 2023 Dec;33 (12) :904-922.|Cell Signal. 2024 May 8:111223.|Cell Signal. 2025 Nov:135:111981.|Cell Stem Cell. 2020 Oct 1;27 (4) :646-662.e7. |Cell Stem Cell. 2022 Sep 1;29 (9) :1346-1365.e10.|Cell Stem Cell. 2022 Sep 1;29 (9) :1366-1381.e9.|Cell. 2024 Jul 25;187 (15) :3936-3952.e19.|Cells. 2023 Dec 30;13 (1) :81.|Cells. 2024 Aug 31.|Cells. 2024 Oct 14;13 (20) :1697.|Chem Biol Interact. 2021 Oct 1:348:109625.|Chem Eng J. 1 January 2023, 138737.|Chem Eng J. 2024 Apr 1, 485, 149884.|Circ Res. 2020 Oct 9;127 (9) :1182-1194.|Clin Mol Hepatol. 2023 Apr;29 (2) :465-481.|Compos B Eng. 2023 Apr 6, 110711.|Connect Tissue Res. 2022 Sep;63 (5) :475-484.|Curr Med Sci. 2024 Aug;44 (4) :718-725.|Dev Cell. 2025 Jun 25:S1534-5807 (25) 00362-4.|Device. 2024 June 12|EBioMedicine. 2024 Nov:109:105390.|EJNMMI Res. 2024 Sep 27;14 (1) :86.|EMBO Mol Med. 2023 Jan 11;15 (1) :e16373.|Engineering. 2025 Aug 27.|Engineering. 2025 Jul 30.|Environ Int. 2025 Jan:195:109266.|Environ Pollut. 2020 Jun;261:114153.|Environ Toxicol Pharmacol. 2023 Nov:104:104301.|Eur J Cell Biol. 2024 May 28;103 (2) :151427.|Eur J Immunol. 2022 Aug;52 (8) :1308-1320.|Eur J Pharmacol. 2025 Apr 11:177623.|Exp Cell Res. 2025 Jun 2;450 (2) :114629.|Exp Mol Med. 2021 Sep;53 (9) :1366-1378.|Exp Mol Med. 2023 Jun;55 (6) :1258-1271.|Exp Mol Med. 2025 Sep;57 (9) :1940-1950.|Exp Ther Med. 2021 Apr;21 (4) :317.|Extracell Vesicle. 2025 Jun.|FASEB J. 2022 Nov;36 (11) :e22580.|FEBS J. 2025 Apr;292 (7) :1696-1709.|Food Chem Toxicol. 2024 Nov:193:115039.|Food Funct. 2025 Aug 26;16 (17) :6786-6799.|Front Cell Dev Biol. 2021 Jun 24:9:670825.|Front Med. 2021 Sep 23;8:746298.|Front Physiol. 2020 Jun 30;11:669.|Fundam Res. 2025 Sep 24.|Gut Microbes. 2022 Jan-Dec;14 (1) :2139978.|Harvard Medical School LINCS LIBRARY|Hepatol Commun. 2025 Aug 15;9 (9) :e0778.|Hum Cell. 2024 Nov 4;38 (1) :13.|Hum Mol Genet. 2023 Jan 6;32 (2) :231-243.|Immunity. 2022 Apr 12;55 (4) :686-700.e7.|Immunity. 2025 Apr 8;58 (4) :946-960.e10.|In Vitro Model. 2025 Mar 5;4 (1) :31-44.|Int Endod J. 2025 Jun;58 (6) :873-889.|Int Immunopharmacol. 2025 Apr 15:155:114657.|Int Immunopharmacol. 2025 Jan 17:148:114068.|Int J Biochem Cell Biol. 2025 Jun 9:186:106820.|Int J Biol Sci. 2022 Aug 29;18 (14) :5459-5474.|Int J Chron Obstruct Pulmon Dis. 2024 Jul 8:19:1591-1601.|Int J Mol Med. 2024 Nov;54 (5) :99.|Int J Mol Sci. 2022 Nov 24;23 (23) :14637.|Int J Mol Sci. 2023 Oct 31;24 (21) :15804.|Int J Mol Sci. 2024 Apr 9, 25 (8), 4138.|Int J Mol Sci. 2025 May 31;26 (11) :5306.|Int J Stem Cells. 2023 May 30;16 (2) :156-167.|Invest Ophthalmol Vis Sci. 2024 Oct 1;65 (12) :19.|Invest Ophthalmol Vis Sci. 2025 Aug 1;66 (11) :61.|iScience. 2021 Oct 19;24 (11) :103303.|iScience. 2023 Aug 29;26 (10) :107773.|J Biochem Mol Toxicol. 2025 Oct;39 (10) :e70500.|J Biol Chem. 2023 Dec;299 (12) :105361.|J Biol Chem. 2025 Jan 27:108235.|J Biol Eng. 2024 Jan 16;18 (1) :7.|J Biosci Bioeng. 2021 Apr;131 (4) :434-441.|J Bone Oncol. 2021 Sep 20:30:100391.|J Cancer Res Clin Oncol. 2024 Sep 19;150 (9) :424.|J Cancer. 2025 Jun 9;16 (8) :2613-2625.|J Cell Mol Med. 2020 Jul;24 (14) :8179-8193.|J Cell Mol Med. 2025 Feb;29 (4) :e70423.|J Clin Invest. 2022 Mar 1;132 (5) :e154993.|J Clin Invest. 2025 Aug 12:e188839.|J Clin Invest. 2025 Jun 2;135 (11) :e184158.|J Clin Med. 2019 Oct 21;8 (10) :1751.|J Exp Clin Cancer Res. 2025 Nov 6;44 (1) :300.|J Immunother Cancer. 2024 Apr 19;12 (4) :e008628.|J Immunother Cancer. 2025 Jan 7;13 (1) :e009356.|J Med Chem. 2019 Jul 11;62 (13) :6083-6101.|J Nanobiotechnology. 2025 Aug 21;23 (1) :579.|J Neuroinflammation. 2024 Apr 10;21 (1) :88.|J Neurosci. 2021 Jan 20;41 (3) :392-407.|J Transl Med. 2023 Oct 10;21 (1) :711.|J Virol. 2021 Feb 24;95 (10) :e02436-20.|J Virol. 2023 May 31;97 (5) :e0177022.|J Virol. 2025 Apr 15;99 (4) :e0176124.|JCI Insight. 2024 Apr 23:e171916.|Laryngoscope. 2025 Jun 7.|Life Sci Alliance. 2025 Oct 13;9 (1) :e202403020.|Life Sci. 2020 Apr 1;246:117419.|Life. 2021 Aug 5;11 (8) :789.|Mater Sci Eng C Mater Biol Appl. 2021 Mar:122:111939.|Med Sci Monit. 2018 May 27:24:3514-3523.|Methods Mol Biol. 2023:2683:53-68.|Methods Mol Biol. 2024:2767:43-52.|Methods Mol Biol. 2024:2767:53-62.|Microsyst Nanoeng. 2024 Jul 15:10:97.|Mol Cancer. 2024 Jan 10;23 (1) :12.|Mol Cancer. 2024 Jun 8;23 (1) :125.|Mol Cancer. 2025 Oct 2;24 (1) :238.|Mol Cell. 2021 Jul 1;81 (13) :2736-2751.e8.|Mol Hum Reprod. 2025 May 26:gaaf017.|Mol Med. 2023 Oct 20;29 (1) :139.|Mol Neurobiol. 2024 Oct;61 (10) :8402-8413.|Nat Cancer. 2025 May;6 (5) :768-785.|Nat Cell Biol. 2022 Jun;24 (6) :858-871.|Nat Chem Biol. 2025 Oct 8.|Nat Commun. 2022 Apr 19;13 (1) :2028.|Nat Commun. 2022 Jun 1;13 (1) :3060.|Nat Commun. 2022 Sep 6;13 (1) :5237.|Nat Commun. 2023 Apr 6;14 (1) :1912.|Nat Commun. 2023 Aug 8;14 (1) :4779.|Nat Commun. 2024 Aug 5;15 (1) :6626.|Nat Commun. 2024 Feb 19;15 (1) :1493.|Nat Commun. 2024 Feb 7;15 (1) :1150.|Nat Commun. 2024 Mar 11;15 (1) :2192.|Nat Commun. 2024 May 30;15 (1) :4590.|Nat Commun. 2025 Aug 5;16 (1) :7190.|Nat Commun. 2025 Feb 26;16 (1) :1999.|Nat Commun. 2025 Jul 1;16 (1) :6016.|Nat Commun. 2025 Mar 17;16 (1) :2635.|Nat Commun. 2025 Mar 26;16 (1) :2941.|Nat Commun. 2025 Sep 29;16 (1) :8541.|Nat Genet. 2024 Feb;56 (2) :294-305.|Nat Genet. 2025 Feb;57 (2) :369-378.|Nat Immunol. 2025 Dec;26 (12) :2218-2226.|Nat Immunol. 2025 Oct;26 (10) :1660-1672.|Nat Methods. 2025 Mar;22 (3) :510-519.|Nat Photonics. 2025 Jul 10.|Nature. 2025 Dec;648 (8092) :166-172.|Nature. 2025 Feb;638 (8049) :225-236.|Nature. 2025 Nov;647 (8088) :257-267.|Naturwissenschaften. 2025 Jul 23;112 (4) :53.|Neurotherapeutics. 2021 Apr;18 (2) :1273-1294.|NPJ Regen Med. 2022 Jun 16;7 (1) :31.|Npj Viruses. 2024 Sep 2;2 (1) :42.|Nutr Metab. 2020 Oct 26;17:91.|Oncogene. 2023 Oct;42 (42) :3113-3126.|Oncol Rep. 2020 Sep;44 (3) :1266-1274.|Oncotarget. 2017 Jul 31;8 (47) :82506-82530.|Patent. US20210284970A1.|Patent. US20220177852A1.|Patent. US20220267735A1.|Patent. US20240018470A1.|Patent. US20240319170A1|Patent. US20240325538A1.|Patent. US20240344020A1|Patent. US20240344020A1.|Patent. US20240344035A1|Patent. US20240344035A1.|Patent. US20250129329A1.|Pharmacol Res. 2023 Jan:187:106615.|Pharmacol Res. 2025 Nov:221:107996.|Phytother Res. 2024 Apr;38 (4) :1863-1881.|PLoS Negl Trop Dis. 2025 Nov 13;19 (11) :e0013725.|PLoS One. 2025 May 30;20 (5) :e0324779.|Protein Cell. 2021 Feb;12 (2) :107-127.|Redox Biol. 2025 Jun:83:103615.|Regen Ther. 2025 Oct 13:30:875-883.|Reprod Toxicol. 2024 Jan:123:108522.|Res Sq. 2025 Apr 24.|Res Sq. 2025 Aug 05.|Res Sq. 2025 Jul 14.|Res Sq. 2025 Mar 10.|Res Sq. 2025 May 22.|Research (Wash D C) . 2022 Aug 3:2022:9832128.|Research (Wash D C) . 2023 Nov 15:6:0270.|Research Square Preprint|Research Square Preprint. 2021 Jan.|Research Square Preprint. 2021 May.|Research Square Preprint. 2021 Oct.|Research Square Preprint. 2022 Jan.|Research Square Preprint. 2022 Jun.|Research Square Preprint. 2023 May 30.|Respir Res. 2022 Mar 25;23 (1) :70.|Sci Adv. 2023 Dec 22;9 (51) :eadi5683.|Sci Adv. 2023 Oct 27;9 (43) :eadg6686.|Sci Adv. 2025 Sep 5;11 (36) :eadz0808.|Sci Rep. 2017 Dec 19;7 (1) :17770.|Sci Rep. 2021 Dec 7;11 (1) :23564.|Sci Rep. 2025 Mar 12;15 (1) :8531.|Sci Rep. 2019 Dec 17;9 (1) :19301. |Sci Total Environ. 2020 Jul 10;725:138433.|Sci Total Environ. 2022 Sep 10;838 (Pt 2) :155811.|Seoul National University. 2029.|Small Methods. 2025 Mar;9 (3) :e2401144.|Small. 2021 Dec;17 (52) :e2104773.|Small. 2021 Jul;17 (28) :e2100546.|Small. 2025 Oct 14:e05653.|SSRN. 2023 Feb 6.|SSRN. 2024 Jan 22.|SSRN. 2025 Aug 19.|STAR Protoc. 2021 Nov 5;2 (4) :100881.|STAR Protoc. 2023 Feb 3;4 (1) :102092.|Stem Cell Res Ther. 2024 Dec 3;15 (1) :463.|Stem Cell Res Ther. 2024 Oct 8;15 (1) :350.|Stem Cell Res Ther. 2025 Apr 12;16 (1) :173.|Stem Cell Res Ther. 2025 May 13;16 (1) :239.|Stem Cell Res Ther. 2019 May 31;10 (1) :155.|Stem Cell Res. 2021 Apr:52:102217.|Stem Cell Res. 2021 Mar:51:102157.|Stem Cell Res. 2022 Sep 15;64:102916.|Stem Cell Res. 2024 Apr:76:103327.|Stem Cell Res. 2024 Jun:77:103399.|Stem Cell Res. 2025 Dec:89:103866.|Stem Cell Res. 2025 Jun 16:87:103752.|Stem Cell Res. 2025 Jun:85:103693.|Stem Cells Int. 2025 Jul 11:2025:5105796.|Theranostics. 2022 Mar 21;12 (6) :2908-2927.|Theranostics. 2022 Mar 28;12 (7) :3131-3149.|Theranostics. 2022 Oct 17;12 (17) :7250-7266.|Theranostics. 2023 May 27;13 (10) :3290-3309.|Theriogenology. 2025 May 29:245:117517.|Tissue Cell. 2025 Aug 28:98:103111.|Toxicology. 2020 Oct;443:152573.|Toxicology. 2024 Nov 9:509:153994.|Transl Lung Cancer Res. 2024 Oct 31;13 (10) :2698-2712.|Transl Lung Cancer Res. 2025 Jun 30;14 (6) :2159-2179.|Tumori. 2024 Oct 27:3008916241291301.|University of California. 2025.|University of Otago. 2025 Oct 7.|Vaccines. 2023 May 17;11 (5) :993.|Virol J. 2025 Apr 15;22 (1) :99.|Virology. 2023 Jun:583:45-51.|Virology. 2024 Dec:600:110233.|Virulence. 2025 Dec;16 (1) :2466482.|Virulence. 2025 Dec;16 (1) :2542455.|Wound Repair Regen. 2025 May-Jun;33 (3) :e70032.
Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

TNIP2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)
47235111 3x 1.0 µg

TNIP2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)

Ask
View Details
3,5-O-Dibenzyl Metaproterenol-d7
HY-W751468 1 Each

3,5-O-Dibenzyl Metaproterenol-d7

Ask
View Details
Human EIF5A siRNA
abx901691-01 15 nmol

Human EIF5A siRNA

Ask
View Details
Human EIF5A siRNA
abx901691-02 30 nmol

Human EIF5A siRNA

Ask
View Details
Anti-MS4A1 (Epitumomab)-SMCC-DM1 ADC
ADC-W-2294 1 mg

Anti-MS4A1 (Epitumomab)-SMCC-DM1 ADC

Ask
View Details
Acetyl-CoA acetyltransferase 1 Rabbit Monoclonal Antibody [KD Validation]
E51K69117 40 µL

Acetyl-CoA acetyltransferase 1 Rabbit Monoclonal Antibody [KD Validation]

Ask
View Details